middle.news
Cambium Bio Secures $2.12M to Power Phase 3 Trials of Elate Ocular
12:11pm on Thursday 31st of July, 2025 AEST
•
Healthcare
Read Story
Cambium Bio Secures $2.12M to Power Phase 3 Trials of Elate Ocular
12:11pm on Thursday 31st of July, 2025 AEST
Key Points
Ethics approvals obtained in Australia and US for Phase 3 trials
First patient dosing on track for Q4 2025, top-line data expected Q4 2026
Net operating cash outflow of A$1.1 million focused on R&D
Closing cash balance low at A$0.166 million, bolstered by recent $2.12M placement
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CMB
OPEN ARTICLE